Conformis, Inc. Logo

Conformis, Inc.

CFMS

(1.0)
Stock Price

2,27 USD

-61.23% ROA

-86.46% ROE

-0.4x PER

Market Cap.

17.881.902,00 USD

83.01% DER

0% Yield

-72.73% NPM

Conformis, Inc. Stock Analysis

Conformis, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Conformis, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.52x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a reasonable amount of debt compared to its ownership (83%), suggesting a balanced financial position and a moderate level of risk.

3 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

4 ROE

The stock's ROE indicates a negative return (-86.46%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-61.23%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-17) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Conformis, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Conformis, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Conformis, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Conformis, Inc. Revenue
Year Revenue Growth
2013 34.597.000
2014 48.186.000 28.2%
2015 66.887.000 27.96%
2016 79.899.000 16.29%
2017 78.115.000 -2.28%
2018 89.789.000 13%
2019 77.429.000 -15.96%
2020 68.761.000 -12.61%
2021 99.860.000 31.14%
2022 62.050.000 -60.93%
2023 52.092.000 -19.12%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Conformis, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2013 13.779.000
2014 15.107.000 8.79%
2015 16.997.000 11.12%
2016 16.608.000 -2.34%
2017 17.136.000 3.08%
2018 16.869.000 -1.58%
2019 12.457.000 -35.42%
2020 11.939.000 -4.34%
2021 14.791.000 19.28%
2022 15.340.000 3.58%
2023 8.632.000 -77.71%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Conformis, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 14.693.000
2014 16.763.000 12.35%
2015 23.191.000 27.72%
2016 25.157.000 7.81%
2017 28.737.000 12.46%
2018 24.622.000 -16.71%
2019 20.895.000 -17.84%
2020 24.244.000 13.81%
2021 28.994.000 16.38%
2022 28.843.000 -0.52%
2023 31.672.000 8.93%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Conformis, Inc. EBITDA
Year EBITDA Growth
2013 -45.336.000
2014 -43.241.000 -4.84%
2015 -55.615.000 22.25%
2016 -57.388.000 3.09%
2017 -55.356.000 -3.67%
2018 -31.302.000 -76.84%
2019 -24.799.000 -26.22%
2020 -25.038.000 0.95%
2021 4.341.000 676.78%
2022 -46.225.000 109.39%
2023 -45.540.000 -1.5%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Conformis, Inc. Gross Profit
Year Gross Profit Growth
2013 7.314.000
2014 17.548.000 58.32%
2015 24.472.000 28.29%
2016 26.707.000 8.37%
2017 28.814.000 7.31%
2018 48.485.000 40.57%
2019 36.737.000 -31.98%
2020 33.715.000 -8.96%
2021 65.681.000 48.67%
2022 23.213.000 -182.95%
2023 7.336.000 -216.43%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Conformis, Inc. Net Profit
Year Net Profit Growth
2013 -47.889.000
2014 -45.722.000 -4.74%
2015 -57.246.000 20.13%
2016 -57.589.000 0.6%
2017 -53.580.000 -7.48%
2018 -43.365.000 -23.56%
2019 -28.478.000 -52.28%
2020 -24.293.000 -17.23%
2021 -2.413.000 -906.76%
2022 -50.473.000 95.22%
2023 -52.044.000 3.02%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Conformis, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 -277
2014 -265 -4.92%
2015 -65 -306.15%
2016 -35 -91.18%
2017 -31 -13.33%
2018 -18 -66.67%
2019 -11 -63.64%
2020 -8 -37.5%
2021 0 0%
2022 -7 100%
2023 -7 14.29%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Conformis, Inc. Free Cashflow
Year Free Cashflow Growth
2013 -50.938.000
2014 -46.153.000 -10.37%
2015 -59.093.000 21.9%
2016 -56.293.000 -4.97%
2017 -43.089.000 -30.64%
2018 -31.041.000 -38.81%
2019 -5.764.000 -438.53%
2020 -21.559.000 73.26%
2021 -10.699.000 -101.5%
2022 -52.071.000 79.45%
2023 -11.598.000 -348.97%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Conformis, Inc. Operating Cashflow
Year Operating Cashflow Growth
2013 -46.826.000
2014 -43.539.000 -7.55%
2015 -54.450.000 20.04%
2016 -49.132.000 -10.82%
2017 -37.856.000 -29.79%
2018 -26.982.000 -40.3%
2019 -2.838.000 -850.74%
2020 -18.310.000 84.5%
2021 -8.399.000 -118%
2022 -50.153.000 83.25%
2023 -11.290.000 -344.22%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Conformis, Inc. Capital Expenditure
Year Capital Expenditure Growth
2013 4.112.000
2014 2.614.000 -57.31%
2015 4.643.000 43.7%
2016 7.161.000 35.16%
2017 5.233.000 -36.84%
2018 4.059.000 -28.92%
2019 2.926.000 -38.72%
2020 3.249.000 9.94%
2021 2.300.000 -41.26%
2022 1.918.000 -19.92%
2023 308.000 -522.73%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Conformis, Inc. Equity
Year Equity Growth
2013 68.960.000
2014 49.827.000 -38.4%
2015 141.212.000 64.71%
2016 94.053.000 -50.14%
2017 46.513.000 -102.21%
2018 36.199.000 -28.49%
2019 16.346.000 -121.45%
2020 11.371.000 -43.75%
2021 100.552.000 88.69%
2022 54.179.000 -85.59%
2023 32.025.000 -69.18%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Conformis, Inc. Assets
Year Assets Growth
2013 83.891.000
2014 71.278.000 -17.7%
2015 159.369.000 55.27%
2016 112.810.000 -41.27%
2017 93.798.000 -20.27%
2018 62.983.000 -48.93%
2019 72.396.000 13%
2020 71.500.000 -1.25%
2021 145.341.000 50.81%
2022 94.048.000 -54.54%
2023 67.781.000 -38.75%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Conformis, Inc. Liabilities
Year Liabilities Growth
2013 14.931.000
2014 21.451.000 30.39%
2015 18.157.000 -18.14%
2016 18.757.000 3.2%
2017 47.285.000 60.33%
2018 26.784.000 -76.54%
2019 56.050.000 52.21%
2020 60.129.000 6.78%
2021 44.789.000 -34.25%
2022 39.869.000 -12.34%
2023 35.756.000 -11.5%

Conformis, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
7.8
Net Income per Share
-5.67
Price to Earning Ratio
-0.4x
Price To Sales Ratio
0.31x
POCF Ratio
-0.37
PFCF Ratio
-0.38
Price to Book Ratio
0.52
EV to Sales
0.32
EV Over EBITDA
-0.47
EV to Operating CashFlow
-0.41
EV to FreeCashFlow
-0.39
Earnings Yield
-2.5
FreeCashFlow Yield
-2.61
Market Cap
0,02 Bil.
Enterprise Value
0,02 Bil.
Graham Number
23.64
Graham NetNet
0.79

Income Statement Metrics

Net Income per Share
-5.67
Income Quality
1.07
ROE
-0.86
Return On Assets
-0.61
Return On Capital Employed
-0.71
Net Income per EBT
1
EBT Per Ebit
1.02
Ebit per Revenue
-0.71
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0.47
Research & Developement to Revenue
0.2
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.33
Operating Profit Margin
-0.71
Pretax Profit Margin
-0.73
Net Profit Margin
-0.73

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-6.09
Free CashFlow per Share
-6.38
Capex to Operating CashFlow
0.05
Capex to Revenue
-0.04
Capex to Depreciation
-0.57
Return on Invested Capital
-0.63
Return on Tangible Assets
-0.61
Days Sales Outstanding
49.87
Days Payables Outstanding
34.32
Days of Inventory on Hand
182.18
Receivables Turnover
7.32
Payables Turnover
10.63
Inventory Turnover
2
Capex per Share
-0.29

Balance Sheet

Cash per Share
3,58
Book Value per Share
4,38
Tangible Book Value per Share
4.38
Shareholders Equity per Share
4.38
Interest Debt per Share
3.96
Debt to Equity
0.83
Debt to Assets
0.39
Net Debt to EBITDA
-0.01
Current Ratio
5.07
Tangible Asset Value
0,03 Bil.
Net Current Asset Value
0,02 Bil.
Invested Capital
0.83
Working Capital
0,04 Bil.
Intangibles to Total Assets
0
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
19257000
Debt to Market Cap
1.49

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Conformis, Inc. Dividends
Year Dividends Growth

Conformis, Inc. Profile

About Conformis, Inc.

Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.

CEO
Mr. Mark A. Augusti
Employee
295
Address
600 Technology Park Drive
Billerica, 01821

Conformis, Inc. Executives & BODs

Conformis, Inc. Executives & BODs
# Name Age
1 Mr. Robert S Howe
Chief Financial Officer & Treasurer
70
2 Ms. Allison Baker
Director of HR
70
3 Mr. Farzin Khaghani
Vice President of U.S. Marketing
70
4 Mr. Mark A. Augusti
Chief Executive Officer, Pres & Director
70
5 Ms. Denise E. Pedulla J.D., M.P.H.
Chief Legal Officer & Corporation Sec.
70
6 Mr. Michael Fillion
Chief Operating Officer
70
7 Eric Rickenbach
Senior Vice President of US Sales
70
8 Mr. Terrance Wong
Senior Vice President of Engineering & Regulatory
70
9 Ms. Erin Henry
Corporation Controller
70
10 Dr. Daniel Steines M.D., MS
Consultant
70

Conformis, Inc. Competitors